|
US9585971B2
(en)
|
2013-09-13 |
2017-03-07 |
California Institute Of Technology |
Recombinant AAV capsid protein
|
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
CN107106689A
(zh)
|
2014-11-05 |
2017-08-29 |
沃雅戈治疗公司 |
用于治疗帕金森病的aadc多核苷酸
|
|
MX2017006216A
(es)
|
2014-11-14 |
2018-08-29 |
Voyager Therapeutics Inc |
Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela).
|
|
KR102584655B1
(ko)
|
2014-11-14 |
2023-10-06 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
|
US11697825B2
(en)
|
2014-12-12 |
2023-07-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scAAV
|
|
JP6754361B2
(ja)
*
|
2014-12-16 |
2020-09-09 |
ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ |
若年型バッテン病のための遺伝子療法
|
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
|
AU2016366549B2
(en)
|
2015-12-11 |
2022-11-10 |
California Institute Of Technology |
Targeting peptides for directing adeno-associated viruses (AAVs)
|
|
US11326182B2
(en)
|
2016-04-29 |
2022-05-10 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
WO2017189964A2
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
RU2758488C2
(ru)
|
2016-05-18 |
2021-10-28 |
Вояджер Терапьютикс, Инк. |
Модулирующие полинуклеотиды
|
|
AU2017268382B2
(en)
|
2016-05-18 |
2023-09-28 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating Huntington's disease
|
|
JP2019531787A
(ja)
|
2016-08-30 |
2019-11-07 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
生物医学的ターゲティング及びデリバリーの方法並びにそれを実行するための装置及びシステム
|
|
US12138298B2
(en)
|
2017-01-30 |
2024-11-12 |
Brainvectis |
Expression vector for cholesterol 24-hydrolase in therapy of polyglutamine repeat spinocerebellar ataxias
|
|
US10898585B2
(en)
|
2017-04-14 |
2021-01-26 |
Ptc Therapeutics .Inc. |
Gene therapy for AADC deficiency
|
|
AU2018261790B2
(en)
|
2017-05-05 |
2024-10-03 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
|
|
WO2018204803A1
(en)
|
2017-05-05 |
2018-11-08 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating huntington's disease
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
CN111132626B
(zh)
|
2017-07-17 |
2024-01-30 |
沃雅戈治疗公司 |
轨迹阵列引导系统
|
|
EP3662060A2
(en)
*
|
2017-08-03 |
2020-06-10 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
AU2018320849A1
(en)
*
|
2017-08-25 |
2020-03-05 |
Ovid Therapeutics Inc. |
Recombinant adeno-associated vectors
|
|
EP3687582A4
(en)
|
2017-09-29 |
2021-07-14 |
Voyager Therapeutics, Inc. |
RESCUE OF CENTRAL AND PERIPHERAL NEUROLOGICAL PHENOTYPE OF FRIEDREICH ATAXIA BY INTRAVENOUS ADMINISTRATION
|
|
US11434502B2
(en)
|
2017-10-16 |
2022-09-06 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (ALS)
|
|
CN111601884A
(zh)
*
|
2017-10-16 |
2020-08-28 |
维格内罗有限责任公司 |
Aav载体
|
|
EP4454654A3
(en)
|
2017-10-16 |
2025-02-19 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
US11458129B2
(en)
|
2017-11-02 |
2022-10-04 |
California Institute Of Technology |
Neurokinin antagonists and uses thereof
|
|
WO2019090000A1
(en)
|
2017-11-02 |
2019-05-09 |
California Institute Of Technology |
Expression of neuropeptides
|
|
US20190202866A1
(en)
*
|
2017-12-22 |
2019-07-04 |
William Marsh Rice University |
Viral nanoparticles and methods of use thereof
|
|
JP7430652B2
(ja)
|
2018-03-05 |
2024-02-13 |
ザ チルドレンズ メディカル センター コーポレーション |
蝸牛および前庭細胞に核酸を送達するための組成物および方法
|
|
JP7378417B2
(ja)
*
|
2018-03-30 |
2023-11-13 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
増強されたヒト膵臓トロピズムを有する新規な組換えアデノ随伴ウイルスキャプシド
|
|
WO2019195449A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
|
CN112543766A
(zh)
|
2018-04-03 |
2021-03-23 |
斯特里迪比奥公司 |
抗体逃避性病毒载体
|
|
EP3773743A1
(en)
|
2018-04-03 |
2021-02-17 |
Stridebio, Inc. |
Virus vectors for targeting ophthalmic tissues
|
|
EP3781174A4
(en)
*
|
2018-04-09 |
2022-01-26 |
Allen Institute |
RESCUE OF VOLTAGE CONTROLLED SODIUM CHANNEL FUNCTION IN INHIBITORY NEURONS
|
|
US12054724B2
(en)
|
2018-04-10 |
2024-08-06 |
President And Fellows Of Harvard College |
AAV vectors encoding clarin-1 or GJB2 and uses thereof
|
|
WO2019198084A1
(en)
*
|
2018-04-12 |
2019-10-17 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Anti-aging compositions and methods of use
|
|
BR112020021903A2
(pt)
|
2018-04-27 |
2021-03-02 |
Rocket Pharmaceuticals, Ltd. |
terapia genética para degeneração do snc
|
|
TW202015742A
(zh)
|
2018-05-15 |
2020-05-01 |
美商航海家醫療公司 |
投遞腺相關病毒（ａａｖ）之組成物和方法
|
|
MX2020012077A
(es)
|
2018-05-15 |
2021-03-09 |
Voyager Therapeutics Inc |
Composiciones y metodos para el tratamiento de la enfermedad de parkinson.
|
|
WO2019241486A1
(en)
|
2018-06-13 |
2019-12-19 |
Voyager Therapeutics, Inc. |
Engineered 5' untranslated regions (5' utr) for aav production
|
|
EP3820885A4
(en)
*
|
2018-07-11 |
2022-04-20 |
The Brigham & Women's Hospital, Inc. |
METHODS AND COMPOSITIONS FOR ADMINISTRATION OF DRUGS ACROSS THE BLOOD-BRAIN BARRIER
|
|
WO2020023612A1
(en)
|
2018-07-24 |
2020-01-30 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
|
WO2020028751A2
(en)
|
2018-08-03 |
2020-02-06 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
KR20210084459A
(ko)
|
2018-09-26 |
2021-07-07 |
캘리포니아 인스티튜트 오브 테크놀로지 |
표적화된 유전자 요법을 위한 아데노-연관 바이러스 조성물
|
|
SG11202103151RA
(en)
|
2018-09-28 |
2021-04-29 |
Voyager Therapeutics Inc |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
AU2019354995B2
(en)
|
2018-10-02 |
2024-12-12 |
Voyager Therapeutics, Inc. |
Redirection of tropism of AAV capsids
|
|
EP3861113A1
(en)
|
2018-10-04 |
2021-08-11 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
|
EP3861107A1
(en)
|
2018-10-05 |
2021-08-11 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding aav production proteins
|
|
EP3864150A4
(en)
|
2018-10-08 |
2022-08-24 |
Allen Institute |
Artificial expression constructs for selectively modulating gene expression in interneurons
|
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
JP2022505106A
(ja)
|
2018-10-15 |
2022-01-14 |
ボイジャー セラピューティクス インコーポレイテッド |
バキュロウイルス／Ｓｆ９システムにおけるｒＡＡＶの大規模産生のための発現ベクター
|
|
EP3873511B1
(en)
|
2018-10-29 |
2022-12-07 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Expression vector for cholesterol 24-hydrolase in therapy of amyotrophic lateral sclerosis
|
|
US20210393713A1
(en)
*
|
2018-11-20 |
2021-12-23 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for targeting the blood-brain barrier
|
|
CN113631225A
(zh)
|
2019-01-18 |
2021-11-09 |
沃雅戈治疗公司 |
用于生产aav颗粒的方法和系统
|
|
CA3128205A1
(en)
*
|
2019-01-30 |
2020-08-06 |
The Broad Institute, Inc. |
Systems for evolved adeno-associated viruses (aavs) for targeted delivery
|
|
CN110437317B
(zh)
*
|
2019-01-30 |
2023-05-02 |
上海科技大学 |
具有变异衣壳蛋白的腺相关病毒及其用途
|
|
US20230193315A1
(en)
*
|
2019-01-31 |
2023-06-22 |
Oregon Health & Science University |
Methods for using transcription-dependent directed evolution of aav capsids
|
|
EP3923995A4
(en)
*
|
2019-02-15 |
2023-05-17 |
Allen Institute |
ARTIFICIAL EXPRESSION RECOMBINANTS FOR THE SELECTIVE MODULATION OF GENE EXPRESSION IN SELECTED NEURON CELL POPULATIONS
|
|
CN113727992A
(zh)
|
2019-03-21 |
2021-11-30 |
斯特里迪比奥公司 |
重组腺相关病毒载体
|
|
AU2020248116B2
(en)
*
|
2019-03-28 |
2025-12-04 |
President And Fellows Of Harvard College |
Engineered adeno-associated (AAV) vectors for transgene expression
|
|
KR20220007056A
(ko)
*
|
2019-04-11 |
2022-01-18 |
캘리포니아 인스티튜트 오브 테크놀로지 |
뇌에서 증진된 특이성을 갖는 바이러스 조성물
|
|
GB201905301D0
(en)
|
2019-04-15 |
2019-05-29 |
Ospedale San Raffaele Srl |
Gene therapy
|
|
WO2020223280A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
US20220243225A1
(en)
|
2019-04-29 |
2022-08-04 |
Voyager Therapeutics, Inc. |
SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
|
|
BR112021021720A2
(pt)
*
|
2019-04-30 |
2021-12-28 |
Univ Pennsylvania |
Composições úteis para tratamento de doença de pompe
|
|
EP3966227A1
(en)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
JP7624410B2
(ja)
*
|
2019-05-21 |
2025-01-30 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
レット症候群の治療におけるコレステロール ２４－ヒドロラーゼのための発現ベクター
|
|
US20220281922A1
(en)
*
|
2019-08-02 |
2022-09-08 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
WO2021030125A1
(en)
|
2019-08-09 |
2021-02-18 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
EP4022070A1
(en)
|
2019-08-26 |
2022-07-06 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
CA3151087A1
(en)
*
|
2019-08-29 |
2021-03-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Adeno-associated viral vectors for crossing the human blood brain barrier
|
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
GB201912863D0
(en)
*
|
2019-09-06 |
2019-10-23 |
Babraham Inst |
Novel method
|
|
GB201913974D0
(en)
*
|
2019-09-27 |
2019-11-13 |
King S College London |
Vector
|
|
WO2021076983A1
(en)
*
|
2019-10-17 |
2021-04-22 |
The Penn State Research Foundation |
Regenerating functional neurons for treatment of spinal cord injury and als
|
|
TW202128736A
(zh)
*
|
2019-10-17 |
2021-08-01 |
美商史崔德生物公司 |
用於治療ｃ型尼曼—匹克病之腺相關病毒載體
|
|
MX2022004353A
(es)
*
|
2019-10-17 |
2022-07-19 |
|
Casete de transferencia de aav.
|
|
AU2020388634A1
(en)
*
|
2019-11-19 |
2022-06-23 |
AskBio Inc. |
Therapeutic adeno-associated virus comprising liver-specific promoters for treating Pompe disease and lysosomal disorders
|
|
MX2022006188A
(es)
*
|
2019-11-22 |
2022-08-22 |
Childrens Hospital Philadelphia |
Variantes del vector viral adenoasociado.
|
|
AU2021206256A1
(en)
|
2020-01-10 |
2022-07-28 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer
|
|
WO2021163357A2
(en)
|
2020-02-13 |
2021-08-19 |
Tenaya Therapeutics, Inc. |
Gene therapy vectors for treating heart disease
|
|
MY209860A
(en)
|
2020-02-13 |
2025-08-07 |
Tenaya Therapeutics Inc |
Gene therapy vectors for treating heart disease
|
|
US20230220014A1
(en)
*
|
2020-04-20 |
2023-07-13 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
|
CN112011571A
(zh)
*
|
2020-04-26 |
2020-12-01 |
辉大(上海)生物科技有限公司 |
一种用于治疗脊髓性肌萎缩的基因治疗药物
|
|
EP4142800A1
(en)
*
|
2020-04-28 |
2023-03-08 |
Genethon |
Use of a synthetic aav capsid for gene therapy of muscle and central nervous system disorders
|
|
CA3181623A1
(en)
|
2020-04-29 |
2021-11-04 |
The Broad Institute, Inc. |
Machine learning accelerated protein engineering through fitness prediction
|
|
EP4143305A4
(en)
*
|
2020-05-01 |
2024-09-11 |
The Broad Institute, Inc. |
GENETICALLY MODIFIED CENTRAL NERVOUS SYSTEM COMPOSITIONS
|
|
US20230203102A1
(en)
*
|
2020-05-13 |
2023-06-29 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
GB202010981D0
(en)
|
2020-07-16 |
2020-09-02 |
Ucl Business Ltd |
Gene therapy for neuromuscular and neuromotor disorders
|
|
WO2022017630A1
(en)
|
2020-07-23 |
2022-01-27 |
Ucl Business Ltd |
GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF
|
|
CA3190309A1
(en)
|
2020-07-27 |
2022-02-03 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
GB202011871D0
(en)
*
|
2020-07-30 |
2020-09-16 |
Cambridge Entpr Ltd |
Composition and method
|
|
BR112023001336A2
(pt)
|
2020-08-05 |
2023-02-14 |
Spacecraft Seven Llc |
Terapia gênica de csrp3 (proteína 3 rica em cisteína e glicina)
|
|
US20230295656A1
(en)
|
2020-08-06 |
2023-09-21 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
CN116194154A
(zh)
|
2020-08-07 |
2023-05-30 |
太空飞船七有限责任公司 |
使用aav载体的plakophilin-2(pkp2)基因疗法
|
|
EP4196494A1
(en)
|
2020-08-17 |
2023-06-21 |
Massachusetts Institute of Technology |
Shank3 gene therapy approaches
|
|
TW202227632A
(zh)
|
2020-08-19 |
2022-07-16 |
美商史崔德生物公司 |
用於治療雷特症候群之腺相關病毒載體
|
|
JP2023538129A
(ja)
*
|
2020-08-21 |
2023-09-06 |
カプシダ， インコーポレイテッド |
好ましい発現レベルを有するアデノ随伴ウイルス組成物
|
|
US12129287B2
(en)
|
2020-09-14 |
2024-10-29 |
President And Fellows Of Harvard College |
Recombinant adeno associated virus encoding clarin-1 and uses thereof
|
|
IL301525A
(en)
*
|
2020-09-21 |
2023-05-01 |
Asklepios Biopharmaceutical Inc |
Methods for treating neurological disease
|
|
CN112194706B
(zh)
*
|
2020-09-30 |
2022-03-08 |
广州派真生物技术有限公司 |
腺相关病毒突变体及其应用
|
|
AU2021363098A1
(en)
|
2020-10-15 |
2023-05-18 |
F. Hoffmann-La Roche Ag |
Nucleic acid constructs for simultaneous gene activation
|
|
TW202233584A
(zh)
|
2020-11-11 |
2022-09-01 |
歐洲分子生物學實驗室 |
用於基因治療之經修飾病毒顆粒
|
|
EP4256065A2
(en)
|
2020-12-01 |
2023-10-11 |
The Trustees of The University of Pennsylvania |
Novel compositions with tissue-specific targeting motifs and compositions containing same
|
|
WO2022187473A2
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
US20240141378A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
JP2024511808A
(ja)
*
|
2021-03-29 |
2024-03-15 |
南京大学 |
ウイルスベクターに基づくｒｎａ送達システム及びその使用
|
|
WO2022221421A2
(en)
*
|
2021-04-13 |
2022-10-20 |
Capsida, Inc. |
Aav compositions with high brain expression for treating mucopolysaccharidosis ii
|
|
WO2022221529A1
(en)
|
2021-04-16 |
2022-10-20 |
Asklepios Biopharmaceutical, Inc. |
Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
|
|
EP4334334A1
(en)
|
2021-04-23 |
2024-03-13 |
The Trustees of The University of Pennsylvania |
Novel compositions with brain-specific targeting motifs and compositions containing same
|
|
AU2022307365A1
(en)
|
2021-07-08 |
2024-02-01 |
Tenaya Therapeutics, Inc. |
Optimized expression cassettes for gene therapy
|
|
WO2023049710A1
(en)
*
|
2021-09-21 |
2023-03-30 |
California Institute Of Technology |
Viral compositions for targeting the nervous system and the lung
|
|
MX2024004217A
(es)
|
2021-10-08 |
2024-06-26 |
Dyno Therapeutics Inc |
Variantes de cápside y métodos de uso de estas.
|
|
WO2023073526A1
(en)
|
2021-10-25 |
2023-05-04 |
Novartis Ag |
Methods for improving adeno-associated virus (aav) delivery
|
|
KR20240113624A
(ko)
|
2021-11-02 |
2024-07-22 |
보이저 테라퓨틱스, 인크. |
Aav 캡시드 변이체 및 이의 용도
|
|
WO2023093905A1
(zh)
|
2021-11-29 |
2023-06-01 |
上海瑞宏迪医药有限公司 |
Aadc、gdnf多核苷酸及其用于治疗帕金森病
|
|
CN114107231B
(zh)
*
|
2021-12-13 |
2023-08-18 |
重庆大学 |
实现全脑突触后神经元胞体标记的重组腺相关病毒及其应用
|
|
WO2023147374A2
(en)
|
2022-01-25 |
2023-08-03 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
|
CN116554278A
(zh)
*
|
2022-01-30 |
2023-08-08 |
上海玮美基因科技有限责任公司 |
变异型腺相关病毒及其在疾病治疗中的应用
|
|
WO2023155918A1
(zh)
|
2022-02-21 |
2023-08-24 |
上海瑞宏迪医药有限公司 |
Vegf结合分子及其医药用途
|
|
EP4482970A1
(en)
|
2022-02-23 |
2025-01-01 |
Massachusetts Institute of Technology |
Methods for upregulating shank3 expression
|
|
JP2025514794A
(ja)
*
|
2022-04-22 |
2025-05-09 |
ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア |
ヒト上衣特異的プロモーターおよびその使用方法
|
|
WO2023240158A2
(en)
*
|
2022-06-07 |
2023-12-14 |
Oregon Health & Science University |
Mutant adeno-associated virus (aav) capsids
|
|
WO2023240236A1
(en)
*
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
TW202421787A
(zh)
|
2022-09-06 |
2024-06-01 |
美商特納亞治療股份有限公司 |
保護心臟之心臟病療法
|
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
GB2622629A
(en)
|
2022-09-23 |
2024-03-27 |
Sania Rx Ltd |
Method
|
|
WO2024100145A1
(en)
|
2022-11-08 |
2024-05-16 |
Ospedale San Raffaele S.R.L. |
Polynucleotide and vector
|
|
WO2024175604A1
(en)
|
2023-02-21 |
2024-08-29 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for the treatment of sanfilippo syndrome type iiib
|
|
CN120936709A
(zh)
*
|
2023-03-09 |
2025-11-11 |
新加坡科技研究局 |
经工程化以增强组织转导和特异性的腺相关病毒的新组合物
|
|
TW202502803A
(zh)
|
2023-03-10 |
2025-01-16 |
美商戴諾治療公司 |
衣殼多肽及其使用方法
|
|
WO2024194491A1
(en)
|
2023-03-22 |
2024-09-26 |
Ospedale San Raffaele S.R.L. |
Gene therapy
|
|
AU2024242380A1
(en)
*
|
2023-03-31 |
2025-11-06 |
Exegenesis Bio Singapore Pte. Ltd. |
Variant aav9 capsid proteins and uses thereof
|
|
WO2024215653A1
(en)
|
2023-04-10 |
2024-10-17 |
Tenaya Therapeutics, Inc. |
Guide rnas, vectors, and virions for targeting mutations in the pln gene
|
|
WO2024215655A1
(en)
|
2023-04-10 |
2024-10-17 |
Tenaya Therapeutics, Inc. |
Cardioprotective bag3 therapies
|
|
WO2024229389A1
(en)
*
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2024229425A1
(en)
*
|
2023-05-04 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2024233422A1
(en)
|
2023-05-05 |
2024-11-14 |
Massachusetts Institute Of Technology |
Shank3 gene therapy approaches
|
|
WO2024238807A2
(en)
|
2023-05-16 |
2024-11-21 |
Affinia Therapeutics Inc. |
Recombinant aavs with improved tropism and specificity
|
|
TW202516019A
(zh)
|
2023-06-29 |
2025-04-16 |
賓州大學委員會 |
具中樞神經系統靶向模體的突變aav及含有其之組成物
|
|
WO2025021839A1
(en)
|
2023-07-25 |
2025-01-30 |
Institut National de la Santé et de la Recherche Médicale |
Method to treat metabolic disorders
|
|
WO2025032158A1
(en)
|
2023-08-08 |
2025-02-13 |
Institut National de la Santé et de la Recherche Médicale |
Method to treat tauopathies
|
|
TW202525832A
(zh)
|
2023-08-31 |
2025-07-01 |
美商戴諾治療公司 |
衣殼多肽及其使用方法(二)
|
|
CN117264912A
(zh)
*
|
2023-09-25 |
2023-12-22 |
中国科学院深圳先进技术研究院 |
一种重组腺相关病毒颗粒、重组腺相关病毒载体系统及其应用
|
|
WO2025073890A1
(en)
|
2023-10-06 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Method to capture circulating tumor extracellular vesicles
|
|
GB202316264D0
(en)
|
2023-10-24 |
2023-12-06 |
Ospendale San Raffaele S R L |
Gene therapy
|
|
WO2025090858A1
(en)
|
2023-10-27 |
2025-05-01 |
Biogen Ma Inc. |
Methods for identifying aav capsid variants with desired characteristics
|
|
US20250152744A1
(en)
*
|
2023-11-15 |
2025-05-15 |
Genzyme Corporation |
Methods of treating neurodegenerative disorders
|
|
WO2025157848A1
(en)
|
2024-01-23 |
2025-07-31 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the intravenous treatment of sanfilippo syndrome type iiib
|
|
WO2025171227A1
(en)
|
2024-02-08 |
2025-08-14 |
Dyno Therapeutics, Inc. |
Capsid polypeptides and methods of use thereof
|
|
WO2025186293A1
(en)
|
2024-03-06 |
2025-09-12 |
Institut National de la Santé et de la Recherche Médicale |
Chmp2b mutants for use for treating infection
|
|
GB202406331D0
(en)
|
2024-05-07 |
2024-06-19 |
Sania Rx Ltd |
Capsid
|